Gln and Glu constitute a metabolic hub in cellular physiology. An increased demand for Gln by transformed cells has been recognized by biochemists for almost a century, and it has been linked to its role as an abundant circulating respiratory fuel 1 . Notably, Gln carbons can support anabolism through entering the TCA cycle through glutaminolysis. Only specific tumour types exhibit Gln dependency [2] [3] [4] [5] [6] [7] [8] [9] , and its genetic and metabolic basis remains debatable. In certain cancer models, the inhibition of glutaminase (GLS), which deaminates Gln to Glu, reduces proliferation and tumorigenicity 10 . Conversely, GLS2 can be induced by the tumour suppressor p53 (ref. 11) , and in human hepatocellular carcinoma, β-catenin increases the expression of GS, which catalyses the reversed GLS reaction 12 . Originally, tuning of the Gln-Glu cycle was observed in the central nervous system 13 where Glu is the most abundant neurotransmitter 14 . Unlike astrocytes, glioma cells can release neuro-excitotoxic amounts of Glu, potentially promoting tumorigenesis 15 . Gln addiction has been proposed as a mark of GBM, the most aggressive glioma 4 . Here, we dissected the differential metabolic roles of Gln-derived carbon and nitrogen atoms in sustaining anabolism and growth in six human established GBM cell lines, in primary GBM stem-like cells, and in normal astrocytes. Additionally, Gln-related metabolism was investigated in both primary orthotopic murine xenografts and in GBM patients, leading to the identification of a GBM-astrocyte metabolic crosstalk.
RESULTS

Gln starvation reduces GBM cell proliferation unsystematically
To explore their growth response to different nutrient supplies, GBM cells were incubated either in DMEM containing supra-physiological concentrations of glucose and lacking some of the non-essential amino acids, or in a newly formulated SMEM, containing nutrient concentrations comparable to human serum ( Supplementary Table 1 ). 20 25 Supplementary Fig. 1b . (e) Growth inhibition caused by Gln starvation. Mean ± s.e.m. n = 3 independent experiments. (f) Scatter plot of the doubling time obtained for the cell lines in Gln-fed conditions, in relation to growth inhibition caused by Gln starvation. Mean ± s.e.m. n = 3 independent experiments. In a-d, the data derive from one experiment performed twice (a-c), or three times (d). Raw data from independent repeats are provided in Supplementary Table 5 .
Both media were supplemented with various concentrations of Gln (Fig. 1a ). In serum-like medium, all cell lines grew comparably to or faster than cells cultured in DMEM. In both media, the minimal Gln concentration required for maximal growth was below 0.65 mM, hereafter used as the control concentration. In the absence of Gln, cells grew faster in SMEM, demonstrating that medium formulation affects the response to Gln deprivation. Gln starvation hindered proliferation to different extents ( Fig. 1b and Supplementary Fig. 1a ) without inducing cell death, contrary to previous reports 3, 4 , and to their response to glucose withdrawal (Fig. 1c ). DNA flow-cytometry analysis showed that Gln starvation did not cause cell cycle arrest at any particular phase ( Fig. 1d and Supplementary Fig. 1b ). Overall, Gln withdrawal resulted in cell line-specific growth inhibition, ranging from 20% for U251 and SF188, to 80% for LN18 cells (Fig. 1e) , independently of the initial proliferation rate (Fig. 1f ).
Gln-based anaplerosis is not essential for the proliferation of GBM cell lines
To investigate cellular metabolic alterations on Gln starvation, the exchange rate of metabolites between cells and medium was analysed by high-performance liquid chromatography-mass spectrometry (HPLC-MS). Gln was the second most consumed nutrient by all cell lines ( Supplementary Fig. 2 and Supplementary Table 2 ). However, no clear relationship emerged between Gln consumption and Gln dependency ( Fig. 2a and Supplementary Fig. 3a) . In contrast, all cell lines showed a net secretion of Glu despite its presence in the (c-f) Cells were incubated as in a,b and the levels of intracellular Gln, Glu, acetyl-CoA and oleate isotopologues are shown. Mean ± s.e.m. n = 3 independent experiments. (g,h) LN18 and SF188 cells were incubated for 24 h with/without Gln in media where glucose (g) or alanine (h) was fully replaced by 13 C 6 -glucose or 15 N 1 -alanine, respectively. The isotopologue distributions of Glu released in the medium are shown. Mean ± s.e.m. n = 3 independent experiments. (i) Scatter plot of Glu secretion observed in the absence of Gln, in relation to the growth inhibition caused by Gln starvation. Mean ± s.e.m. n = 3 independent experiments. (j) A schematic representation of the X − c activity in the context of Glu metabolism. (k) LN18 cells were incubated for 24 h with/without Gln in media supplemented or not with Glu, α-ketoglutarate dimethylester (dm-αKG), sulphasalazine (SSZ) or cystine, at the indicated concentrations, and the secretion and consumption rates of Glu are shown. (l-o) LN18 cells were incubated as in k and the intracellular levels of Glu (l), aspartate (m), citrate (n) and the reduced form of glutathione (o) are shown as a percentage of the untreated control. (p) LN18 cells were incubated for 72 h as described for k. Cell number is shown as a percentage of the untreated control. Mean ± s.e.m. n = 4 independent experiments. P values refer to a two-tailed t-test for unpaired samples. (q,r) Cells were pre-incubated in medium with 0, 2.5, 5, 10, 15, 30 µM BPTES for 3 h. At t = 0, the medium was replaced with one containing 13 C 5 -Gln. The abundance of 13 C 5 -Glu (q) or 13 C 5 -Gln (r) in the medium was monitored over time. In all conditions, cells were exposed to 0.3% DMSO. (s) Cells were incubated in medium with/without 2.5 µM BPTES for 72 h, and counted. DMSO was 0.3% in all conditions. Mean ± s.e.m. n = 3 independent experiments. In k-o,q,r, the data derive from one experiment performed once (k-o) or twice (q,r). Raw data from independent repeats are provided in Supplementary Table 5 . medium (Fig. 2b) . Tracing 13 C 5 -labelled Gln revealed that 38 ± 8% to 60 ± 19% (GUVW and U87 cells, respectively) of the Gln consumed was deamidated and secreted as 13 C 5 -Glu ( Fig. 2a,b ). Unexpectedly, even Gln-starved cells discharged Glu (Fig. 2b , empty bars). Here, intracellular Gln was almost exhausted ( Fig. 2c ) and Glu concentration fell by more than 50% ( Fig. 2d ), yet neither acetyl-CoA ( Fig. 2e ) nor oleate ( Fig. 2f ) levels were reduced, re-affirming that Gln does not sustain fatty acids biosynthesis under normoxic condition [16] [17] [18] [19] [20] . Consistently, in all cell lines, less than 15% of the citrate was derived from reductive carboxylation ( 13 C 5 -citrate; Supplementary  Fig. 3b ), and labelled acetyl-CoA and oleate were barely detectable ( Fig. 2e,f) .
To identify the carbon source for Glu synthesis under Gln starvation, Gln-deprived LN18 and SF188 cells were incubated with 13 C 6 -glucose. In both cases, the contribution of glucose carbons to Glu was markedly increased (Fig. 2g ). Accordingly, alanine consumption was increased ( Supplementary Fig. 2 , inset), providing the nitrogen required for Glu production ( Fig. 2h ). Moreover, a strong direct correlation between Glu efflux and growth inhibition was observed ( Fig. 2i ), suggesting that on Gln withdrawal, Glu efflux limits the intracellular Glu available for reactions essential for growth.
To test whether Glu efflux indeed limited both its availability and the proliferation of Gln-starved cells, LN18 cells were incubated with sulphasalazine, an inhibitor of X − c , a Glu/cystine antiporter ( Fig. 2j ) that is active in glioma cells 15 , or with 4 mM Glu, largely exceeding the K i for X − c (ref. 21) . In both conditions Glu release was largely inhibited (Fig. 2k ). Consistently, the activation of X − c by increasing the extracellular concentrations of cystine, boosted Glu efflux ( Fig. 2k ), firmly associating X − c with the escape of Glu from GBM cells. Inhibiting X − c prevented the drop in intracellular Glu, aspartate and citrate, caused by Gln withdrawal (Fig. 2l -n). The levels of glutathione, an alternative metabolic fate for Glu, were also substantially decreased on Gln starvation, and significantly replenished by Glu and sulphasalazine ( Fig. 2o ). However, the drop in glutathione on Gln starvation was not accompanied by its increased oxidation ( Supplementary Fig. 3c ), indicating that Gln delimits Glu availability for glutathione biosynthesis without causing oxidative stress. Furthermore, adding the membrane-permeable dimethylester of α-ketoglutarate (dm-αKG) to Gln-starved cells doubled the Glu efflux ( Fig. 2k ) and replenished Glu, aspartate, citrate and glutathione intracellular pools ( Fig. 2l-o) . Overall, in the absence of Gln, X − c inhibition or dm-αKG supplementation restored the cellular Glu, aspartate, citrate and glutathione levels to that of non-starved cells. However, maintaining the levels of these metabolites only moderately rescued the proliferation of Gln-starved cells ( Fig. 2p ). Together with the observations that, under Gln starvation, intracellular oleate was unaffected ( Fig. 2f ), and glucose-dependent Glu production increased ( Fig. 2g -h), these results imply that the contribution of Gln to growth is largely independent of anaplerosis.
To evaluate this directly, BPTES, a GLS inhibitor, was employed. The kinetics of Gln-derived Glu secretion from LN18 and SF188 cells showed that BPTES inhibited GLS activity ( Fig. 2q ). Accordingly, the rate of Gln consumption was reduced ( Fig. 2r ). Nevertheless, at the minimum effective concentration, BPTES did not affect the growth of the GBM lines ( Fig. 2s and Supplementary Fig. 3d -i) confirming that here, GLS and Gln-based anaplerosis are dispensable for maximal growth.
Glutamine synthetase sustains purine availability and cell growth under Gln starvation
Next, a genome-scale constraint-based metabolic modelling approach was employed 22 , searching for reactions that become essential when Gln is removed from the SMEM medium. According to the model, GS was the only enzyme essential for sustaining biomass production after Gln starvation (Supplementary Note).
Together, GS and GLS control Gln homeostasis by catalysing opposite reactions (Figs 2j and 3a) . The messenger RNA levels of GS and GLS in all cell lines revealed no pattern of Gln dependency ( Supplementary Fig. 4a ). Although it has been proposed that c-Myc determines Gln addiction by increasing GLS expression 3, 23, 24 , MYCinduced lung tumours were shown to increase GS expression 2 . In line with this, SF188 cells, harbouring MYC amplification 25 , and expressing high levels of c-Myc ( Fig. 3b and Supplementary Fig. 4a ), showed the highest levels of GS mRNA and protein ( Fig. 3b and Supplementary Fig. 4a ). In most cell lines, GS protein levels rose on Gln deprivation (Fig. 3b ). Furthermore, GS protein levels tend to increase in cells with decreased sensitivity to Gln withdrawal ( Fig. 3c ). Nevertheless, GS did not match the residual low amount of Gln found in Gln-starved cells (Fig. 2c ). To investigate this apparent discrepancy, the metabolic flux through GS was assessed by the incorporation of 15 N-labelled ammonia ( 15 NH 4 + ) into Gln in LN18 and SF188 cells, which exhibit low and high levels of GS, respectively. Significant levels of 15 N-labelled Gln were indeed detected in SF188 but not in LN18 cells (Fig. 3d ). Next, SF188 and U251 cells, exhibiting high levels of GS and low sensitivity to Gln withdrawal, were incubated with L-methionine sulphoximine (MSO), a selective irreversible inhibitor of GS. MSO sensitized cells to Gln starvation and, further, abolished the protective effect of Glu supplementation ( Fig. 3e ). To complement this approach, GS expression was stably silenced in these cells by two short hairpin RNA (shRNA) sequences ( Fig. 3f ). On Gln starvation, cell proliferation ( Fig. 3g ) as well as colony formation ( Fig. 3h and Supplementary Fig. 4b ) was lowered by GS silencing. Supplementation with the GS substrates Glu and ammonia rescued Gln-deprived control cells more effectively than GS-silenced cells ( Fig. 3g,h) .
To corroborate the causal link between Gln biosynthesis and Gln dependency, GS was overexpressed in LN18 cells, which exhibit low GS levels and high sensitivity to Gln deprivation. To this end, LN18-derived clones stably expressing infrared fluorescent protein alone 26, 27 (iRFP) or iRFP and GS were established. To eliminate intrinsic clonal variability, GS expression and its effect on growth under Gln starvation were evaluated in multiple clones (6 iRFP and 9 iRFP-GS). After five days of starvation, growth of iRFP control cells reached, on average, 16 ± 5% of control Gln-fed cells, and iRFP-GS clones reached, on average, 54 ± 12% ( Fig. 4a ). Under Gln supplementation, the iRFP-GS 5 clone proliferated slower than iRFP controls. This was not rectified by GS inhibition with MSO ( Fig. 5b ), consistent with a reported non-metabolic, anti-proliferative role of GS (ref. 28 ). Nevertheless, iRFP-GS 5 , but not control iRFP 4 cells, proliferated and formed colonies in Gln-free medium, and this growth advantage was blocked by MSO ( Fig. 4b,c ). These results imply that under Gln starvation the amidation of Glu catalysed by GS sustains cell growth. In line with this, when supplemented with 15 N 1 -ammonia, GS-expressing cells exhibited 15 N incorporation into ∼50% of the total Gln pool, even when Gln fed ( Fig. 4d ). When incubated with 15 N 1 -ammonia without Gln, residual intracellular Gln was higher in iRFP-GS 5 cells compared with control iRFP 4 cells, and produced entirely by GS as judged by 15 N incorporation ( Fig. 4d ).
To explore the essentiality and metabolic fate of de novo synthesized Gln under Gln starvation, we employed flux imbalance analysis 29 . In silico, nucleotide biosynthesis delimited cell growth, with a higher weighted cost for purine biosynthesis (Supplementary Note). Indeed, regardless of GS status, Gln removal only marginally affected the levels of the pyrimidine nucleotide uridine monophosphate (UMP; Fig. 4e ). Moreover, the contribution of GS-derived Supplementary Table 5 . 
+ -+ -Gln
Gln Gln biosynthesis, which requires Gln-derived nitrogen, was also sustained in iRFP 4 cells during Gln starvation ( Supplementary Fig. 4c ). In contrast, 5-aminoimidazole-4-carboxamide ribotide (AICAR), a purine precursor for inosine monophosphate (IMP), dropped to undetectable levels in Gln-starved iRFP 4 cells (Fig. 4f ). The ammonia-derived AICAR ( 15 N 2 -isotopologue) in Gln-starved iRFP-GS 5 cells demonstrates that GS contributes the two Gln nitrogen atoms required for its biosynthesis (Fig. 4f ). Thus, 15 N 2 -IMP accumulated in Gln-deprived iRFP-GS 5 cells, but not in iRFP 4 cells (Fig. 4g ). The IMP found in iRFP-GS 5 starved cells corroborates the reported inhibitory effect of Gln deprivation on IMP dehydrogenase 30 , and suggests that under these conditions over-activity of GS exceeds the rate of IMP conversion to AMP and GMP. Indeed, AMP levels were not significantly affected by either Gln presence or GS overexpression (Fig. 4h ). Moreover, ATP and GTP levels, indices of the cell's bioenergetic state, were comparable between iRFP-GS 5 and iRFP 4 starved cells ( Fig. 4i,j) . Conversely, the fractions of 15 N-labelled AMP, ATP and GTP found in iRFP-GS 5 cells exceeded those of iRFP 4 cells, demonstrating that, under Gln starvation, GS sustains de novo biosynthesis of purine nucleotides.
Notably, the reduction in IMP caused by Gln starvation in the six GBM cell lines correlated with Gln dependency (Fig. 4k,l) . Accordingly, adenosine, but not guanosine or pyrimidine nucleosides, partially restored Gln-independent growth of iRFP 4 cells ( Fig. 4m ). Furthermore, the combined addition of adenosine and Glu compensated for the lack of exogenous Gln in iRFP 4 cells (Fig. 4m ), and Glu alone completely restored proliferation of iRFP-GS 5 starved cells (Fig. 4n ). In both lines, MSO prevented the Glu rescue, confirming that under Gln starvation, Glu availability determines Gln production rather than anaplerosis. The effect of adenosine on Gln-starved cells was MSO-independent ( Fig. 4m ,n), because it supported proliferation downstream of GS.
Primary human GBM stem-like cells are self-sufficient for Gln requirements
The clinical relevance of studying established glioma cell lines has been questioned owing to their inability to form tumours that recapitulate human pathology. Therefore, we used three primary patient-derived GBM cell lines (E2, R10, R24), generating paired populations of differentiated cells (DIFF) and glioma stem-like cells 31 (GSC). Stem cell markers such as CD133, Olig2 and Sox2 were predominantly expressed in GSC but not DIFF; however, the astrocytic marker glial fibrillary acidic protein (GFAP) was not consistently associated with the DIFF population (Fig. 5a ). The expression of GS was markedly higher in all GSC compared with DIFF ( Fig. 5a ) and whereas DIFF proliferation was attenuated in the absence of Gln, GSC grew independently of Gln supplementation (Fig. 5b ). Once more, the growth of Gln-starved DIFF and GSC was abolished by MSO ( Fig. 5b) .
Next, the exchange rates ( Fig. 5c,d ) and intracellular composition of metabolites ( Fig. 5e -h) were analysed in these primary Gln-starved or control cells, in the presence of 15 N 1 -ammonia. The net Gln consumption was consistently higher in DIFF compared with GSC, whereby R24-GSC demonstrated no net Gln consumption ( Fig. 5c ). As the intracellular 15 N 1 -Gln fraction shows, GSC have higher GS activity compared with DIFF and sustain higher residual Gln levels on starvation (Fig. 5e ). The differences in Glu exchange rates were also striking: GSC exhibited a net uptake of Glu, whereas the reverse occurred in DIFF (Fig. 5d ). Also, on Gln withdrawal, intracellular levels of citrate ( Fig. 5g ) decreased in DIFF, but remained unaltered in GSC, showing that Gln-derived anaplerosis was redundant to the stem-like population. Finally, ammonia-derived 15 N incorporation into purine nucleotides ( 15 N 2 -AMP) under Gln starvation was greater in GSC compared with the paired DIFF.
Human GBM tumours rely on in situ de novo Gln synthesis As shown above, GS activity, largely determining Gln dependency, varies between established and primary human GBM cells. Similarly, tissue microarray (TMA) analysis showed that GS expression varies between human GBM patients (n = 209), resembling a Gaussian distribution ranging from tumours with low GS levels, comparable to neurons (25% of patients), to high-expression tumours comparable to astrocytes (15%; Fig. 6a,b ). However, GS expression did not predict patient median survival ( Fig. 6c ). Of twenty biopsies, from which core TMA were sampled, five showed substantial intratumoral GS immunostaining heterogeneity (three examples are reported in Supplementary Fig. 5 ). Most GBMs showed either GS uniformity, or a mosaic infiltration of GS-positive cells, suggesting autonomous intratumoral Gln biosynthetic capacity. To assess this hypothesis in human tumours, seven GBM patients were injected with 13 C 6 -glucose before surgery, and metabolites were extracted from the resected tumours and their oedematous margins. The metabolic analysis reliably discriminated between tumour and adjacent tissues by using the choline to creatine ratio, a parameter for classifying brain tumours by magnetic resonance spectroscopy 32 (Fig. 6d ). No significant difference in Gln content was observed between tumour and adjacent tissues ( Fig. 6e ). At the time of resection, 13 C 6 -glucose enrichment in sera ranged between 16 and 50% ( Fig. 6f, and Supplementary Fig. 6a ). Glucose-derived 13 C-Gln was detected in 6/7 tumours and in 7/7 adjacent oedematous tissues with an enrichment ranging between 1 and 12% (Fig. 6g ). In 3/5 patients the fraction of glucose-derived Gln in the tumour was higher than in the serum sample, and so not in equilibrium with the circulating Gln, suggesting that the tumour Gln pool is synthesized in situ and/or provided by adjacent normal brain.
To complement the analysis in patients, mice were orthotopically transplanted with a GS-positive human GBM (P3, Fig. 6h ) and injected with 13 C-labelled glucose or Gln ∼20 min before tissue extraction. An enrichment of 44 ± 3% of 13 C 6 -glucose was found in the blood at the time of tissue sampling. The intracellular hexose phosphate pool derived from 13 C 6 -glucose was ∼10% and 5% in tumour and contralateral brain tissue, respectively (Fig. 6i ). Concomitantly, ∼10% and 15% of the total Gln was labelled ( 13 C 2 ) from 13 C 6 -glucose in tumours and contralateral brain, respectively (Fig. 6i) , consistent with GS activity in those tissues. After 13 C 5 -Gln injection, the enrichment in circulating 13 C 5 -Gln at the time of tissue sampling was 17 ± 1%. Isotopologue distribution analysis showed an enrichment in 13 C 5 -Gln of <5% in both tumour and contralateral brain tissues (Fig. 6j) , whereas in the liver, 13 C 5 -Gln presented 12% of the total ( Supplementary Fig. 6e ). Products of glutaminolysis, such as Glu and α-ketoglutarate, were labelled below 1% in both tumour and brain tissues but ∼5% in liver ( Fig. 6j and Supplementary Fig. 6e ). These results suggest slow kinetics both for Gln uptake from the blood, and for glutaminolysis in GBM and brain tissues, compared with liver. Similar results were obtained on constant carotid artery 13 C 5 -Gln infusion: within two hours, circulating 13 C 5 -Gln levels plateaued at ∼20% enrichment, with an overall ∼70% increase in steady-state levels of Gln ( Supplementary Fig. 6f ). Here too, 13 C 5 -Gln and The values are mean ± s.e.m. n = 3 mice for all conditions, except for contralateral brain of mice injected with glucose, where 2 mice were used. For i,j, raw data from independent repeats are provided in Supplementary Table 5 .
glutaminolysis products were scarce in tumour and contralateral brain ( Supplementary Fig. 6h ,i) indicating that physiologically, circulating Gln does not significantly supply Gln to the brain or the tumour within it. Next, Erwinase, an enzyme that temporarily depletes circulating asparagine (Asn) and significantly reduces Gln (refs 9,33; Fig. 7a ), was injected daily 5 times per week into mice bearing GS-negative orthotopic GBM xenografts (T101, Fig. 7b ). Erwinase reduced intratumoral and intracerebral Asn but not Gln (Fig. 7c) . The diffuse morphology of GS-negative tumours impaired the volumetric quantification of tumours by magnetic resonance imaging (MRI) (Fig. 7d ). Histological reconstruction to assess tumour burden (Fig. 7e ) revealed no significant differences between control and Erwinasetreated groups (Fig. 7f ). Together, these results indicate that Gln is not provided to GBM by the blood, and so the proximity of GS-positive astrocytes and GS-negative glioma cells ( Fig. 7b ,g as representatives) suggests that astrocytes may be a source of Gln. Indeed, when mice bearing GS-negative GBM xenografts (T407, Fig. 7g ) were infused with 15 N 1 -ammonia into the carotid artery for 4 h, the fraction of 15 -N-Gln was ∼5% in both tumour and contralateral brain tissues ( Fig. 7h) indicating that they are a secluded, autonomous compartment for Gln biosynthesis and utilization, where GS-expressing cells supply Gln to GS-negative ones.
Gln-starved GBM cells feed on astrocyte-derived Gln
To assess this potential interaction, rat primary cortical astrocytes were cultured and their Gln requirement and metabolism investigated. Similar to GBM cells, the minimal Gln concentration required for maximal astrocyte growth was ∼0.65 mM (Fig. 8a) . Nonetheless, astrocyte proliferation was barely affected by Gln deprivation (Fig. 8b) . As observed in the human TMA (Fig. 6a ), GS protein levels in astrocytes and in the highest expressing GBM cells were comparable (Fig. 8c) . However, only astrocytes demonstrated no net Gln consumption but rather, rapid Glu uptake ( Fig. 8d,e ), in line with the expression of excitatory amino acid transporters in this cell type 34 . Under Gln starvation, Glu consumption was unaffected and paralleled by an equimolar net Gln efflux ( Fig. 8d,e ). The absence of Gln in the medium reduced intracellular Gln, but not Glu (Fig. 8f,g) . Moreover, 13 C 6 -glucose tracing showed that only 30-40% of both intracellular Glu and Gln (Fig. 8f,g) was glucose-derived. Astrocytes maintained ∼30% of the control level of intracellular Gln under Gln starvation (Fig. 8f,h) , fitting with high GS expression. Gln maintenance depended on GS activity, as seen from both 15 N 1 -ammonia tracing and GS inhibition by MSO (Fig. 8h ). Moreover, GS inhibition markedly elevated the intracellular amounts of its substrate, Glu (Fig. 8i) , without changing the steady-state levels of the Gln product, AMP (Fig. 8j ). However, combined Gln withdrawal and GS inhibition significantly reduced the labelled fraction of AMP derived from de novo synthesis ( 15 N 2 and 15 N 3 ; Fig. 8j ), and hindered proliferation (Fig. 8k ).
Finally, in co-culture, astrocytes enabled the proliferation of GS-negative LN18 iRFP 4 cells without Gln supplementation (Fig. 8l) . Moreover, Transwell co-culturing of these cells showed that the factor conveying growth was diffusible (Fig. 8m,n) . The addition of Erwinase, which depletes both Asn and Gln, prevented the rescue of Gln-deprived cells by astrocytes (Fig. 8m,n) . As Asn was present in the media during all Gln-starvation experiments, and because astrocytes consume Asn but produce and secrete Gln ( Fig. 8d and Supplementary  Fig. 6k ), these results designate astrocyte-derived Gln as the growthsupporting factor for Gln-starved GBM cells.
DISCUSSION
Gln plays multiple metabolic and non-metabolic roles. Consequently, the dependency of cancer cells on Gln is difficult to discern. Nevertheless, it was demonstrated here that the Gln requirement in GBM goes beyond anaplerosis (Fig. 2q-s) . We identified two alternative metabolic determinants for Gln sensitivity: Glu release through the X − c antiporter; and GS-dependent conversion of Glu to Gln. GS and X − c seemingly compete for cytoplasmic Glu, which during Gln starvation becomes limiting (Fig. 2d,l) . Nevertheless, the rescuing effect achieved by maintaining intracellular Glu through X − c inhibition depends on GS activity (Fig. 3e,h,g and Fig. 4m,n) . These results demonstrate that on Gln starvation, Glu conversion to Gln constitutes a critically limiting reaction required for growth. This metabolic trait applies to established GBM lines, and to naive primary cells. Indeed, when primary GBM cells were maintained in a stemlike state, GS expression was markedly increased (Fig. 5a ) and Glu was taken up rather than released (Fig. 5d ). Both responses enable growth of glioma stem-like cells independent of extracellular Gln (Fig. 5b) . The fate of newly synthesized Gln in both established and primary GBM cells was followed by 15 N 1 -ammonia tracing, identifying the AMP biosynthesis pathway as a significant player in Gln dependency (Fig. 4d-j and Fig. 5h ).
GS is found in most human GBM (Fig. 6a,b) , and its expression is associated with poor prognosis 35 , although this is not supported by our TMA study. However, we show that GS expression varies greatly between tumours, ranging from negative, comparable to GS expression in neurons, to high, as in normal astrocytes. This variation accords with a Gln-rich tumour microenvironment, which alleviates the need to synthesize Gln. Nevertheless, in agreement with previous reports 36, 37 , it is shown here that most human GBM, as well as GS-proficient orthotopic GBM xenografts, withdraw carbons from the TCA cycle (cataplerosis) to synthesize Gln by means of GS. When compared with the liver, GBM are inclined towards net Gln synthesis, rather than glutaminolysis ( Fig. 6i and Supplementary  Fig. 6d ). Accordingly, the circulation provides minimal amounts of Gln to normal brain 38 and GBM ( Fig. 6l and Supplementary  Fig. 6f,h,i) . Moreover, a marked decrease in circulating Gln levels did not affect tumour growth (Fig. 7a-h) , and GBM expressing low GS had levels of ammonia-derived Gln comparable to contralateral brain (Fig. 7j ). The stability of Gln levels may explain the heterogeneity in GS expression between patients ( Fig. 6b ) and within some tumours ( Supplementary Fig. 5 ): GS-positive astrocytes and/or GBM cells (potentially GSC) excrete Gln that supports the growth of GSnegative GBM cells. Indeed, primary astrocytes in culture retain the metabolic traits of Glu uptake, GS-dependent Gln synthesis and Gln secretion, and support the proliferation of GS-negative, Gln-auxotrophic GBM cells ( Fig. 8l-n) . Thus, this brain-to-tumour metabolic communication portrays a scenario in which Gln, provided by astrocytes, feeds GS-negative cancer cells (Fig. 3g) . Indeed, GS-positive cellular protrusions of astrocytes surround GS-negative GBM cells in orthotopic xenografts and human tumours ( Fig. 7b ,g (k) Astrocytes were incubated for 6 days with/without 0.65 mM Gln, and 1 mM MSO and counted. (l) Astrocytes were grown to confluence in multiwell plates. iRFP 4 cells were seeded in wells with/without astrocytes, and with/without Gln. The fluorescence of iRFP 4 cells in representative wells is shown. The experiment was performed twice with comparable results. (m) Astrocytes were grown to confluence in multi-well plates. iRFP 4 cells seeded in Transwell inserts were co-cultured with/without astrocytes, with/without Gln, and with/without Erwinase (Erw) as indicated. Fluorescence of iRFP 4 cells in representative inserts is shown. At day 5 astrocytes were stained with sulphorodamine-B and the fluorescence of representative wells is shown. (n) Quantification of the iRFP 4 fluorescence as described for m. In a,b,d-k,n, the data derive from one experiment performed twice. Raw data from independent repeats are provided in Supplementary Table 5 .
and Supplementary Fig. 5p ). This 'parasitic' behaviour of cancer cells could divert the physiological Gln-Glu cycle in the brain and, indeed, an increase in epileptic seizures has been reported for patients with GBM expressing low GS (ref. 39) .
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary Information is available in the online version of the paper METHODS Cell cultures. The human glioblastoma cell lines MOG-G-UVW, LN-18, LN-229, SF-188, U-251 MG and U-87 MG (hereafter referred to as GUVW, LN18, LN229, SF188, U251 and U87, respectively) were obtained from the following sources: GUVW: frozen stock originally isolated by I. Freshney at the University of Glasgow, UK; LN18 and LN229: ATCC; SF188: Brain Tumour Tissue Bank University of California San Francisco, USA; U251 and U87: kindly provided by K. Ryan at the Cancer Research UK-Beatson Institute, UK and A. Chalmers at the University of Glasgow, UK, respectively. The cell lines were authenticated using Promega GenePrint 10 system (STR multiplex assay that amplifies 9 tetranucleotide repeat loci and the Amelogenin gender determining marker). No cell line used in the manuscript has been found in the ICLAC database of commonly misidentified cell lines. Cortical astrocytes were generated from the cortex of P7 Sprague-Dawley rat pups (unclassified gender). Briefly, both cortices were removed from each pup cleared of meninges and enzymatically dissociated and purified as previously described. Tissue from 2 pups was added to each 75 cm 2 tissue culture poly-L-lysine-coated flask (13 µg ml −1 , Sigma). Astrocytes prepared in this way were over 95% pure as assessed by immunoreactivity to glial fibrillary acidic protein 40 .
All of the cell lines tested negative for mycoplasma with MycoAlert when tested with the Mycoplasma Detection Kit (Lonza). Cells were maintained in DMEM (Invitrogen 21969-035) supplemented with 2 mM glutamine and 10% FBS. All of the experiments were performed on cells seeded and incubated for at least 24 h in a serum-like medium, SMEM, formulated as reported in Supplementary Table 1 , and supplemented with 10% FBS, dialysed against a semi-permeable cellulose membrane (3.5 kDa MW cutoff).
For co-culture experiments 30,000 astrocytes per well were plated in a 24-well plate and allowed to grow to confluence, and then an LN18-derived clone stably expressing infrared fluorescent protein, iRFP 4 , was seeded at 25,000 cells per well or 5,000 iRFP 4 cells per Transwell (Costar, CLS3413) in complete medium for direct or Transwell co-culture experiments, respectively. The next day, iRFP 4 cell cultures were extensively washed with PBS, Transwells were inserted in wells containing astrocytes, and the medium was replaced with the conditions indicated in Fig. 8l ,m. Half of the medium volume was renewed daily for the whole duration of the experiments. Growth was assessed by measuring fluorescence with a Licor Odyssey scanner and quantified using Image Studio 2.0 software.
E2, R10 and R24 human glioblastoma cells were obtained and cultured as previously reported with minor modifications 31 . In brief, differentiated (DIFF) cells were maintained in advanced DMEM/F-12 (Gibco) supplemented with 10% FBS and 2 mM Gln, and glioma stem-like cells (GSC) were maintained in advanced DMEM/F-12 supplemented with B27 (1%, Invitrogen), N2 (0.5%, Invitrogen), 4 µg ml −1 heparin, 20 ng ml −1 fibroblast growth factor 2 (bFGF, Sigma), 20 ng ml −1 epidermal growth factor (EGF, Sigma), 1 mM pyruvate and 2 mM Gln. For all of the experiments stem cells were seeded and incubated in SMEM supplemented as described above, and DIFF cells were seeded and incubated in advanced DMEM/F-12 supplemented with 10% dialysed FBS. Glutamine (0.65 mM) was added as indicated in Fig. 5 .
Cell number assessment. Cells were plated at a density of 20,000 cells per well in 24-well plates. Cell number was assessed at the specified experimental time as follows: each well was washed twice with PBS, trypsinized, cells were re-suspended in a Casyton solution and counted with a Casy cell counter. The doubling time (DT) was obtained using the exponential growth equation with GraphPad prism 5.0. The percentage of growth inhibition was calculated according to the following equation:
Cell death assessment. Cells were plated at a density of 15,000 cells per well in 12-well plates. After 2 days, cells were placed in medium with or without glucose and Gln, and supplemented with CellTox Green Dye (1:1,000, Promega, G8731). Cells were incubated in an IncuCyte FLR (EssenBioScience) for 72 h, during which time bright-field and fluorescence pictures were taken every hour. For each time point a cell death index was calculated by dividing the number of dead cells on the confluency index.
Cell cycle analysis. Culture media and cells were collected, centrifuged and washed with PBS. Cells were then fixed with cold methanol and stained with a PBS solution containing propidium iodide (100 µg ml −1 ) and RNAase A (250 µg ml −1 ). DNA nuclear content was measured by using a Beckton Dickinson FACScan flow cytometer and data were analysed with FlowJo software.
Tissue microarray (TMA) and immunohistochemistry (IHC). The collection of human biopsy tissue was approved by the regional ethical committee at Haukeland University Hospital, Bergen, Norway (REK 013.09). All patients gave a written informed consent for tumour biopsy collection and signed a declaration permitting the use of their biopsy specimens for research. Core tissues of glioblastoma cancer tissue (n = 209) were identified by a pathologist, and collected from representative areas of tumours derived from patients' surgical resection. Tissue cores were collected in triplicate for each patient. Follow-up details including date and cause of death were collected. For IHC analysis of the TMA, and mouse brain slices, the following procedure was followed. Epitope retrieval was performed at 98 • C for 15 in citrate buffer, pH 6. The immunostaining was performed using an EnVision System-HRP DAB (Dako, K4006). The cores were incubated overnight at 4 • C with primary antibody. Cores were counterstained with haematoxylin, dehydrated and coverslipped. The staining was quantified using a weighted histoscore method with a final value range 0-300. The intensity of the immunostaining observed for normal astrocytes was classified as 300 and used as reference. Low-, medium-and high-glutamine synthetase (GS)-expressing groups were defined as reported in Fig. 6b . For TMA and IHC the following antibodies were diluted in a solution of 5% BSA in TBS-Tween and employed at the specified dilutions: purified mouse anti-human monoclonal GS antibody (BD Transduction Laboratories, Cat. 610518, clone 6 at a final concentration of 250 ng ml −1 ); mouse monoclonal anti-human nestin antibody (Abcam ab6320, clone 3k1, 1:500); mouse monoclonal anti-human EGFR antibody (Dako 7239 clone E30, 1:200, 1 h at room temperature). For tumour volume quantification by IHC the mouse brain was paraffin embedded and entirely sliced into sections of 8 µm. Two sections were loaded on each slide, and one slide in every 10 was stained for EGFR. Digital images were acquired with a Leica SCN400 Slide Scanner, loaded into Matlab, calibrated and pixels positive for the staining were identified and used to quantify tumour volume. All IHC staining images shown are representative of three or more sections.
Metabolic study in GBM patients. Before undergoing surgical tumour resection, seven GBM patients were infused for 15 min with 20 g of 13 C 6 -glucose. During the operation, tissue fragments from the core and peripheral region of the tumour were stereotactically sampled (∼200 mg for each region). On average the specimens were snap-frozen 47 min after the end of the glucose injection (range 30-80 min). Peripheral blood samples were also collected at the same time of tissue sampling. Sub-fragments of frozen tissues (15-25 mg) were further dissected from peripheral and core regions of the tumour, and from oedematous adjacent tissue. The samples were extracted on dry ice and processed as described below for human orthotopic GBM xenografts.
Informed consent was obtained from all human subjects involved in the study; the heavy-isotope administration and the collection of tissue from surgical resections were approved by the regional ethical committee at Haukeland University Hospital, Bergen, Norway (REK 2010/130-2).
Primary orthotopic human GBM xenografts. Patient-derived GBM xenografts
were generated as previously reported 41, 42 . Briefly, GBM patient-derived spheroids were stereotactically implanted into the right frontal cortex of 8-12-week-old, male and female, NOD SCID mice (Charles River) using a Hamilton syringe. After 4-6 weeks a P3 GBM tumour was fully established in the brain, and U-13 C 6 -glucose or U-13 C 5 -glutamine (Cambridge Isotope Laboratories) was injected as a bolus in the tail vein at a dose of 1 mg g −1 and 0.15 mg g −1 of body weight respectively. Twentytwo minutes after injection, the animals were euthanized, organs were dissected, and tumour and contralateral brain fragments were snap-frozen. For intracarotid infusion the mice were kept under anaesthesia with ketamine medetomidine isoflurane and underwent a surgical procedure to expose the right carotid artery. Ammonia incorporting 15 N 1 was infused at 4.7 µmol kg −1 min −1 , 0.833 µl min −1 for 4 h in NOD SCID mice (Charles River) xenografted orthotopically with a T407 GBM. Glutamine ( 13 C 5 ) was infused at 13 µmol kg −1 min −1 , 0.125 µl min −1 for 4 h in 8week-old, female, Swiss Nu/Nu mice (Charles River) xenografted orthotopically with the GS-positive T16 GBM. To assess the effects of Erwinase, 8-week-old, female, Swiss Nu/Nu mice (Charles River) were implanted with T101 tumour spheroids (six per mouse). Forty-two days after implantation mice were randomly assigned to Erwinase treatment or control group. Erwinase was injected intraperitoneally at 5 U g −1 of body weight, five times per week, where 1 international unit is defined as the amount of enzyme required to generate 1 µmol of ammonia per minute at pH 7.3 and 37 • C. The treatment continued for 6 weeks. Mice of the control group were intraperitoneally injected with saline solution. Mice were euthanized six hours after the last injection and tumour and contralateral brain fragments were snap-frozen for metabolic analysis. Whole brains were immediately fixed in 4% paraformaldehyde for ex vivo MRI. For metabolic analysis, 10-20 mg of tissue was extracted with a beads mill (Qiagen, Tissuelyser) in a solution containing 20% water, 50% methanol, 30% acetonitrile (25 µl of extraction solution per milligram of tissue). The extracts were spun down at 16,000g for 10 min and supernatants were stored at −80 • C for LC-MS analysis. Human glioblastoma biopsies were obtained from the Neurosurgery Department of the Centre Hospitalier in Luxembourg (CHL). All patients had provided written informed consent, with procedures that were approved DOI: 10.1038/ncb3272 for the project (project number: REC-LRNO-20110708) by the National Research Ethics Committee for Luxembourg (CNER). The handling of the animals and the surgical procedures were performed in accordance with the European Directive on animal experimentation (2010/63/EU) and the national regulations of Luxembourg and the local ethical committee (the Animal Welfare Structure (AWS) LIH) approved the protocol (protocol number: LRNO-2014-06).
MRI analysis. At the end of Erwinase treatment the brains of the 20-week-old Swiss
Nu/Nu mice with T101 tumours (7 female mice per group) were collected and fixed in 4% paraformaldehyde. Ex vivo scans were acquired on a 7T micro-MRI system (Bruker PharmaScan) using a mouse brain volume coil. The T2-weighted MRI protocol used a fast spin echo sequence with TE = 36 ms, TR = 4,300 ms, and 63 µm in plane resolution. The diffusion-weighted imaging sequence used EPI readout with TE = 28.5 ms, TR = 7,000 ms and b-values ranging from 500 to 6,000 s mm −2 in 3 directions. The tumours were independently delineated by two users (A.O. and O.K.) using Paravision 5.0 (Bruker).
Immunoblotting. Cells were washed twice with cold PBS and lysed in RIPA buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton, 2,5 mM sodium pyrophosphate, 1 mM glycerophosphate) supplemented with 1 mM Na 3 VO 4 , 1 mM NaF and protein inhibitor cocktail. Protein concentration was determined with the bicinchoninic acid assay (Thermo scientific) using BSA as a standard. Equal amounts of protein were mixed with Laemmli buffer 4× (250 mM Tris-HCl, pH 6.8, 8% SDS, 40% glycerol, 0.4 M dithiothreitol), warmed at 95 • C for 5 min, and loaded on 10% gels for SDS-PAGE. After electrophoretic separation, proteins were blotted onto 0.22 mm nitrocellulose membrane (Millipore), blocked with 5% non-fat milk in TBS-Tween, and incubated at 4 • C overnight with the following antibodies: glutamine synthetase (BD Transduction Labs, 610517, clone 6, 1:1,000), β-tubulin (Sigma Aldrich, T5201, clone AA2, 1:5,000), GLS (Abcam, ab60709, 1:1,000), c-Myc (Cell Signaling Technology, 5605, clone D84C12, 1:1,000), glial fibrillary acidic protein (Dako, Z0334, 1:10,000), SOX2 (Abcam, ab75485, clone 57CT23.3.4, 1:1,000), CD133 (Miltenyi Biotec, W6B3C1, clone W6B3C1, 1:1,000), Olig2 (R&D system, AF2418, 1:500), actin (Santa Cruz Biotechnology, sc-1616-R, 1:1,000). Membranes were then washed and incubated with secondary donkey antirabbit (Licor 926 32213, 1:10,000) or donkey anti-mouse (Licor 926 32212, 1:10,000). The IR scanning was performed using a Licor Odyssey scanner and acquired using Image Studio 2.0. All western blots shown are representative of two experiments unless otherwise indicated. Metabolites extraction and HPLC-MS. The established cell lines were plated in 6-well plates in complete DMEM from 125,000 to 250,000 cells per well. After 24 h the medium was replaced with SMEM supplemented with 10% dialysed FBS. Stem-like and differentiated primary glioma stem cells were plated at 150,000 cells per well in 6-well plates in SMEM supplemented as described in the cell culture section. When optimal confluence was reached (1-3 days) 3 wells were extracted as described below, and the protein was determined (µg prot t 0 ). The medium in the remaining wells was changed with 2 or 7 ml per well of complete SMEM for the analysis of metabolites present in the medium or in the cells, respectively. U-13 C 5 -Gln (0.65 mM, Cambridge Isotopes), U-13 C 6 -glucose (5.56 mM, Cambridge Isotopes) or 15 N 1 -ammonia (0.8 mM, Sigma) was supplemented as indicated in the figures. Cells, as well as parallel cell-free wells, were incubated for 24 h at 37 • C. At the end of the incubation, an aliquot of the media was diluted 1:50 in a solution containing 20% water, 50% methanol and 30% acetonitrile. The medium derived from wells devoid of cells was used to estimate the exchange rates of metabolites. For the profiling of intracellular metabolites, monolayers were rapidly washed 3 times with ice-cold PBS and extracted with an aqueous solution of 50% methanol, and 30% acetonitrile. Both media and cell extracts were centrifuged at 16,000g for 10 min at 4 • C and the supernatants were analysed by means of HPLC-MS. The extracted cell monolayer was used for protein determination (µg prot t 24 ) with a Lowry assay. Aliquots of freshly prepared SMEM, without FBS, and spiked with known concentrations of lactate were processed in parallel and used as a reference for metabolite quantification. The secretion/consumption rate for a specific metabolite (x) was obtained according to the equation x = (2 × ( metabolite)/µg prot t 0 + µg prot t 24 ), where metabolite = ((x)nmol medium with no cell − (x)nmol medium with cells). For the LC separation of medium samples a ZIC-HILIC (SeQuant) with a guard column (Hichrom) was used. Mobile phase A was a 0.1% formic acid solution in water and mobile phase B was 0.1% formic acid in acetonitrile. The flow rate of the mobile phases was kept at 100 µl min −1 and the gradient was as follows: 0 min 80% of B, 12 min 50% of B, 26 min 50% of B, 28 min 20% of B, 36 min 20% of B and 37 to 45 min 80% of B. For the separation, cell extracts were injected on a ZIC-pHILIC column with a guard column. (Mobile phase C: 20 mM ammonia carbonate plus 0.1% ammonia hydroxide in water. Mobile phase D: acetonitrile.) The flow rate was kept at 100 µl min −1 and gradient as follows: 0 min 80% of D, 30 min 20% of D, 31 min 80% of D and 45 min 80% of D. The Exactive Orbitrap mass spectrometer (Thermo Scientific) was operated in a polarity switching mode.
Cell transfection and infection. For stable transfection 10 cm dishes of 80% confluent LN18 cells were incubated for 9 h with 10 ml of FBS-free transfection medium containing 1 µg ml −1 of DNA (vector containing P2A-iRFP IRES puro alone, or GS-P2A-iRFP IRES puro), and 2 µl ml −1 of Lipofectamine2000 (Invitrogen). The transfection mixture was than replaced with 10 ml of complete DMEM. The following day medium was changed and cells were cultured for 3 weeks in selection medium containing 2 µg ml −1 of puromycin. Fluorescent colonies were visualized with the Licor Odyssey scanner, picked and amplified in selection medium to obtain stable cultures. For the establishment of cell lines expressing shRNA against glutamine synthetase (GS), four human unique shRNA sequences of 29 nucleotides, and a scrambled negative control non-effective shRNA cassette (NTC) in a lentiviral GFP vector, were employed according to the manufacturer's instructions (TL312740a: 5 -GGTGAGAAAGTCCAGGCCATGTATATCTG-3 ; TL312740b: 5 -GAATGGTGCAGGCTGCCATACCAACTTCA-3 ; TL312740c: 5 -TGGTACTGGAGAAGGACTGCGCTGCAAGA-3 ; TL312740d: 5 -GGCACAC CTGTAAACGGATAATGGACATG-3 ; TR30021ntc: 5 -GCACTACCAGAGCTA ACTCAGATAGTACT-3 , Origene). TL312740b, TL312740d and TR30021ntc are reported in the manuscript as GS shRNA1 GS shRNA2 and NTC shRNA respectively. Briefly, lentiviruses were produced by co-transfecting HEK293T cells with each shRNA plasmid, lentiviral plasmid psPAX2-1, and packaging plasmid pVSV-G-1, according to a standard calcium phosphate procedure. Supernatants containing virus were collected, filtered and frozen in stocks at −80 • C. For infection of recipient cells the supernatant was thawed, mixed with hexadimethrine bromide (Sigma, H9268, 8 µg ml −1 ) and incubated for 24 h with the cells. Infected cells were selected for 2 weeks in medium containing 1-3 µg ml −1 puromycin.
Colony-forming assay. iRFP and iRFP-GS-expressing cells were plated at 300 cells per well in 6-well plates in complete SMEM, in the absence or presence of 0.65 mM Gln and 1 mM MSO as indicated. After 3 weeks, colonies were fixed with trichloroacetic acid, stained with SRB and plates were scanned using a Licor Odyssey scanner. Images were acquired using Image Studio 2.0. SF188 and U251 cells expressing NTC shRNA and GS shRNA sequences were seeded in 6-well plates, at 500 and 350 cells per well for SF188 and U251 cells, respectively. Cells were incubated in complete SMEM and supplemented as indicated in the legend of Fig. 3 . Twelve to seventeen days after seeding, colonies were fixed, stained, and representative images obtained as described above. For the quantification of colony surface area an ImageJ macro was designed and run. The values obtained from the macro were normalized for the exact number of days cells were incubated, and presented as percentage of relative control.
Reagents. U-13 C 5 -L-Glutamine and U-13 C 6 -D-Glucose (CLM-1822 and CLM-1396, respectively) were obtained from Cambridge Isotopes Laboratories, 15 N 1 ammonium chloride (299251), sulphasalazine (S0883), MSO (M5379), BPTES (SML0601) and dm-αKG (349631) were obtained from Sigma Aldrich. Compound 968 (352010) was obtained from Calbiochem. BPTES and compound 968 were dissolved 10 mM in DMSO. Erwinase was obtained from Eusa Pharma, an international division of Jazz Pharmaceuticals. All amino acids, nucleosides, and nitrogenous bases used in the study were obtained from Sigma Aldrich.
Genome-scale constraint-based metabolic modelling.
A detailed description of the metabolic modelling methods and results is provided in the Supplementary Note.
Statistical methods.
No statistical method was used to predetermine sample size.
For the animal studies, the experiments were not randomized, and the investigators
SUPPLEMENTARY NOTE
Genome-scale constraint-based metabolic modeling.
To predict the effects of Gln deprivation on cellular growth we simulated the experiment in a computational model. Our simulations were run on the generic model of human metabolism, Recon1 1 . Flux Balance Analysis (FBA) 2 
and Flux
Imbalance Analysis (FIA) 3 were used to query the model and predict cellular growth rate, essential genes and growth limiting metabolites.
Simulated experimental conditions:
In order to simulate the in vitro conditions we set the concentrations of nutrients available to the model to match those of the SMEM growth medium. The list of components used for the model growth medium and their concentrations are reported in Supplementary Table 3 . To account for biomass production, we added a growth reaction representing the steady-state consumption of biomass compounds required for cellular proliferation. The stoichiometric coefficients of the growth reaction represent the relative molecular concentrations of 42 essential metabolites.
The addition of a biomass reaction is common practice when modeling proliferating cells, and was described in detail in previous work 4,5
Searching for conditionally essential reactions:
We queried the model for conditionally essential reaction knockouts -reactions that are non-essential on SMEM medium, yet become essential when Gln is removed from the medium. The flux through a conditionally essential reaction is thus predicted to modulate the cell's sensitivity to Gln deprivation. We used an FBA approach to identify conditionally essential reactions. For each reaction , we simulated the knockout of and used FBA to simulate the maximal cellular growth rate (denoted !! ) when Gln is present\absent from the growth medium (denoted +, −, respectively). was defined as conditionally essential if !!,!"#! > 0 and !!,!"#! = 0.
Our analysis revealed a single conditionally essential reaction: Glutamine synthetase (GS). The knockout of GS was also found to completely abolish the model's ability to replenish intra-cellular Gln.
Finding growth limiting metabolites:
We next explored which metabolites became growth limiting during Gln deprivation.
FIA allows for the prediction of growth limiting metabolites by calculating a shadow price for each metabolite . The shadow price of (denoted ( )) represents the potential increase in cellular growth resulting from the synthesis or secretion of a small quantity of . A negative ( ) signifies that is growth limiting, whereas ( ) = 0 signifies that is not growth limiting. Positive shadow prices are rare and theoretically signify toxic metabolites, whose secretion or detoxification would require resources that could otherwise be used for growth.
Gln deprivation was simulated by removing Gln from the model's growth medium and restricting the flux through GS to half the amount necessary to sustain maximal growth. FIA was used to calculate shadow prices for all biomass constituents, revealing a negative shadow price for all nucleotides. The shadow prices were seen to directly represent the number of Gln-derived amide nitrogens necessary for the synthesis of each nucleotide -1 amide nitrogen for TMP and UMP, 2 for AMP and CMP, 3 for GMP. Calculated shadow prices are shown in Supplementary Table 4 .
We then calculated the total flux passing through each metabolite , denoted by ( ) and weighted the shadow prices by multiplying by ( ). This weighting was performed in order to determine which nucleotide imposes the greatest burden on cellular growth. The weighting has two justifications:
(1) One caveat of FIA is that the shadow price of is unrelated to the amount of limiting resource (Gln-derived nitrogen in our case) invested in the synthesis of . At the end of this section we provide a toy network example which better illustrates this property of FIA.
(2) The total flux ( ) passing through metabolite represents 's direct contribution to biomass production as well as 's involvement in other growth related pathways, where participates as an intermediate metabolite or a co-factor. Hence, ( ) provides a proxy to the significance of to the cellular growth process. We expect some of the cellular effort to be vested in maintaining the steady state concentrations of metabolites with high ( ) values.
Detailed calculation of the weighted shadow prices:
For each metabolite , ( ) was multiplied by ( ), the minimal absolute flux passing through under FBA formulation. A flux distribution with minimal absolute fluxes was calculated using the following linear problem:
. .
= 0
(2) ≤ ≤ Finally, the weighted cost of was estimated by ( ) • ( ). The results of this calculation are given in Supplementary Table 4 .
Following weighting AMP was shown to incur the heaviest cost to the cell, in spite of its synthesis requiring the same amount of Gln-derived nitrogens as CMP, and less than GMP. Specifically, AMP is the most limiting, due to its use as a precursor for Gln suggest that low intracellular Gln concentrations that permit protein and pyrimidine synthesis, may be limiting for purine biosynthetic pathways.
Toy network example
For the sake of clarity, we repeated the analysis of growth limiting metabolites on a toy network. Supplementary Figure 7A depicts a toy network with five intracellular metabolites and a growth medium comprised of two extracellular metabolites. The numbers on the edges signify the stoichiometric coefficients. The growth medium, in our example, contains 36 (arbitrary) units of metabolite and 64 units of metabolite . The aim of the analysis is to determine which metabolite incurs the greatest cost to the cell in terms of the resources spent on its synthesis.
Supplementary Figure 7B shows an optimal flux distribution across the toy network.
Reaction fluxes are shown in red. Note that in order to calculate the total turnover of a metabolite by a reaction one must multiply the reaction flux by the metabolite's stoichiometric coefficient (i.e. multiply the red and black numbers). The flux distribution reveals that is the limiting resource whereas is abundant. In order to sustain maximal growth, the cell invests 24 units of in synthesizing metabolite and 12 units in synthesizing , making the most costly investment. The synthesis of does not incur any cost in terms of the limiting resource .
The shadow price ( ) of a metabolite in our toy network would be = − / , where is the amount of limiting resource (metabolite ) necessary for synthesizing and is the total amount of limiting resource necessary for producing one unit of biomass. One unit of biomass requires 6 molecules of , 2 molecules of and 3 molecules of . Multiplying each metabolite by its respective cost in we get:
The shadow prices are hence = . It can be seen that has the highest shadow price, even though most of the limiting resource is invested in the synthesis of .
This behavior of FIA can be corrected by taking into account the absolute flux passing through each metabolite. In the optimal flux distribution, the absolute fluxes passing through the biomass constituents are:
= 1 • 12 + 6 • 2 = 24 (7) = 1 • 4 + 2 • 2 = 8 (8) = 1 • 6 + 3 • 2 = 12 (9) (note that in the toy network all product metabolites have a stoichiometric coefficient of 1). By weighting the shadow prices according to the total flux we get = . The weighted cost is directly proportional to the amount of limiting resource invested in the synthesis of each metabolite and shows that poses the heaviest limitation on cellular growth, as desired.
